{"id":3830,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/chloroquine-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"chloroquine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/chloroquine-txt\/","title":{"rendered":"Chloroquine.txt"},"content":{"rendered":"

Chloroquine<\/h1>\n

CLINICAL USE <\/H3><\/p>\n
  • Treatment and prophylaxis of malaria\n
  • Discoid and systemic lupus erythematosus\n
  • Rheumatoid arthritis

    DOSE IN NORMAL RENAL FUNCTION <\/H3>\n
  • Orally (as base)\n
  • Malaria treatment: 600 mg, followed by 300 mg 6\u20138 hours later, then 300 mg\/day for 2 days\n
  • Malaria prophylaxis: 300 mg once a week on the same day each week (start 1 week before exposure to risk and continue until 4 weeks after leaving the malarial area\n
  • SLE: 150 mg daily\n
  • Rheumatoid arthritis: 150 mg daily; maximum 2.5 mg\/kg

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :319.9 (515.9 as phosphate), (436 as sulphate)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :50\u201370<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 42\u201347<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :>100<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :10\u201360 days\/5\u201350 days

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 50% of normal dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone \u2013 avoid concomitant use\n
  • Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin \u2013 avoid concomitant use\n
  • Anti-epileptics: antagonism of anticonvulsant effect\n
  • Antimalarials: increased risk of convulsions with mefloquine; avoid concomitant use with artemether\/lumefantrine\n
  • Ciclosporin: increases ciclosporin concentration \u2013 increased risk of toxicity\n
  • Digoxin: possibly increased concentration of digoxin\n
  • Lanthanum: absorption possibly reduced by lanthanum, give at least 2 hours apart

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IV, IM\/SC in rare cases

    Rate of Administration <\/H4> IV infusion :\n
  • Administer dose 10 mg\/kg of chloroquine base in sodium chloride 0.9% by slow

    IV infusion <\/H4> over 8 hours followed by 3 further 8 hour infusions containing 5 mg base\/kg (total dose 25 mg base\/kg over 32 hours)

    Comments<\/H4>\n
  • Oral: Do not take indigestion remedies at the same time of day as this medicine\n
  • Chloroquine sulphate inj. is available: 5.45% w\/v (equivalent to 40 mg chloroquine base per mL)

    OTHER INFORMATION <\/H4>\n
  • Excretion is increased in alkaline urine\n
  • Caution in patients with renal or hepatic disease\n
  • Bone marrow suppression may occur with extended treatment\n
  • 150 mg chloroquine base is equivalent to 200 mg of sulphate and 250 mg of phosphate
    \n","protected":false},"excerpt":{"rendered":"

    Chloroquine CLINICAL USE Treatment and prophylaxis of malaria Discoid and<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3830","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3830"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3830\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}